Bethlehem, PA (PRWEB) March 28, 2013
Neuromonics, Inc., is introducing the first device specifically designed to help individuals suffering from mild to moderate tinnitus.
The Neuromonics Sanctuary™ device is the company’s newest product to help tinnitus patients. The company will debut the Sanctuary at the Audiology NOW! Conference April 3-6 in Anaheim, Calif., at Booth No. 1660. Neuromonics also will showcase its Oasis, the FDA-cleared, patented and clinically proven device that offers long-term, significant relief for serious tinnitus sufferers. “With the addition of the Sanctuary, Neuromonics can provide effective, simple treatment for the full range of those dealing with tinnitus,” says Curtis Amann, vice president of marketing and sales for the company.
Tinnitus is often described as buzzing, ringing, hissing, humming, roaring, or whistling that someone hears in the absence of any external sound. More than 50 million people in the United States alone suffer from the condition, according to the American Tinnitus Association. Usually brought on by exposure to loud noise, the problem is especially significant in the military, with more than 34 percent of returning veterans from Iraq and Afghanistan suffering from tinnitus.
The Neuromonics Sanctuary provides relief of tinnitus symptoms by combining relaxing music with a customized neural stimulus. The Sanctuary blends a customized, high-frequency signal with music, providing an on-demand sense of control and relief to the individual. Patients with mild or moderate tinnitus disturbance can experience relief within minutes of their tinnitus assessment, according to Amann.
Ease of use
The compact Sanctuary device is simple to use, functioning much like familiar consumer music players, and fits easily into patients’ lifestyles, says Amann. Tinnitus sufferers can choose from one of three pre-programmed profiles to find the signal that provides the greatest degree of relief from their particular symptoms. Pressing “play” allows them to listen to calming, relaxing music that interacts with the tinnitus perception.
Individuals use the Sanctuary at times when their tinnitus is bothersome, says Amann. “The Sanctuary provides relief while listening to the device -- when you want it and when you need it.”
Tinnitus sufferers can begin to determine if the Sanctuary is the right choice for them by taking Neuromonics’ online tinnitus assessment. A trained audiology clinician will review the score during an assessment visit and determine if the Sanctuary is the appropriate device. The Neuromonics Sanctuary is a Class II medical device, regulated by the FDA and requiring a prescription from a trained clinician.
The Sanctuary is not a masking device, but rather works to promote new neural connections that will allow the brain to help filter out the tinnitus perception. Key features of the simple device include the following.
Long-term tinnitus relief
The Neuromonics Sanctuary device works with the same principles as the Neuromonics Oasis, the gold standard for long-term reduction of tinnitus disturbance and awareness. The Sanctuary is designed for situational relief. In contrast, the FDA-cleared, patented and clinically proven Neuromonics Oasis, in combination with the Neuromonics Tinnitus Treatment, is a long-term treatment program for those with more severe tinnitus.
Neuromonics, Inc. (http://www.neuromonics.com)
Based in Bethlehem, Pa., Neuromonics, Inc., manufactures and distributes clinically proven, FDA-cleared medical devices to treat tinnitus. The Sanctuary provides situational relief for those suffering from mild to moderate tinnitus. The patented and clinically proven Oasis, working the Neuromonics Tinnitus Treatment, provides long-term significant relief for those with severe tinnitus. With research and development beginning in the early 1990s, Neuromonics has helped thousands of tinnitus sufferers improve their quality of life and overcome the daily life challenges associated with tinnitus. The treatment has been featured on national news media including The Doctors and CNN.
Read the full story at http://www.prweb.com/releases/2013/3/prweb10574661.htm.
Copyright©2012 Vocus, Inc.
All rights reserved